Avid Bioservices Inc (CDMO)

[freethemice]

It has now been over a year since all patients completed treatment in the second-line NSCLC phase IIb trial.
When the revised data is released it will be interesting to know the one-year survival rate. Regardless of whether
the patients received 1mg/kg, or 3 mg/kg, or some combination of the two, the percentage of patients
surviving after one year, compared with the control arm patients, should be a good indicator of how
well bavi works. That would be valuable information for any potential partner.